| Autor: |
Unsworth-White SR; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, UK., Kitchen MO; School of Medicine, Keele, UK.; Urology Department, University Hospitals of North Midlands NHS Trust, UK., Bryan RT; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, UK. |
| Jazyk: |
angličtina |
| Zdroj: |
Future oncology (London, England) [Future Oncol] 2022 Jan; Vol. 18 (1), pp. 105-115. Date of Electronic Publication: 2021 Nov 12. |
| DOI: |
10.2217/fon-2021-0781 |
| Abstrakt: |
Supplies of intravesical Bacillus Calmette-Guérin (BCG), the first-line treatment for most intermediate- and high-risk non-muscle-invasive bladder cancers (NMIBC), have proven unreliable over the past decade. This review considers the evolution of BCG immunotherapy for NMIBC: from the discovery of the antitumour side effects of tuberculosis and subsequently the BCG vaccine, to recent advances in novel immunotherapeutic agents. We summarize the evidence for alternative options to standard intravesical BCG therapy regimens and describe the potential for immune response manipulating drugs in the treatment of NMIBC. These new agents, including immune checkpoint inhibitors, toll-like receptor agonists and recombinant viral vectors, may provide better options in the management of NMIBC in the future. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
